PBM reform is here. What do new transparency and fiduciary rules mean for the industry? Federal legislation, new state laws and proposed reforms are placing pharmacy benefit managers under growing scrutiny.
Managed Healthcare Executive® partnered with Drug Topics® on a timely webinar, PBMs, Transparency and Fiduciary Responsibility, examining how emerging PBM transparency requirements, fiduciary responsibilities and policy reforms could reshape relationships among payers, pharmacies and PBMs.
Watch the recorded discussion now to hear expert perspectives on the evolving regulatory landscape and what these policy changes may mean for managed care strategy and pharmacy benefit operations.
Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.
Model N's Jesse Mendelsohn explains why drug manufacturers argued that a 340B rebates instead of upfront discounts will avoid an overlapping maximum fair price and 340B discounts
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.